• 学术搜索
  • 科研智能体
    • Research Labs
    • AI 阅读
    • AI 文库
    • 深度研究
    • 学者亮点
  • 学术资源
    • AI2000
    • 期刊/会议
    • 学者库
    • 学术API
      MCP&Skill
    • 溯源树
    • 数据集
  • 知识沉淀
    • 学术空间
订阅小程序
旧版功能
aminer vip
开通会员低至0.73元/天
一次搞定AI科研
立即登录
  • English
  • 联系方式
    T

    The University of Texas Health Science Center

    院校EST. 2007
    6,500论文总数
    41.2万引用总数

    The University of Texas System (UT System) is an American government entity of the state of Texas that includes 13 higher educational institutions throughout the state including eight universities and five independent health institutions. The UT System is headquartered in Downtown Austin, and has a total enrollment of nearly 240,000 students (largest university system in Texas) and employs 21,000 faculty and more than 83,000 health care professionals, researchers and support staff. The UT System's $30 billion endowment (as of the 2019 fiscal year) is the largest of any public university system in the United States. As of 2018, Reuters ranks the UT System among the top 10 most innovative academic institutions in the world.

    论文量&引用量时间轴

    机构学者

    论文(6500)

    年份
    起
    –
    止
    排序
    1Expectant Management Vs Medication for Patent Ductus Arteriosus in Preterm Infants: the PDA Randomized Clinical Trial.
    Matthew M Laughon,Sonia M Thomas,Kristi L Watterberg,Kathleen A Kennedy,Martin Keszler, Namisavayam Ambalavanan,Alexis S Davis,Jonathan L Slaughter,Ronnie Guillet,Tarah T Colaizy, C Michael Cotten, Megan A Dhawan,

    Importance:The management of patent ductus arteriosus (PDA) in preterm infants is controversial. Objective:To determine whether expectant management compared with active treatment of a protocol-defined PDA in preterm infants decreases the incidence of death or bronchopulmonary dysplasia (BPD). Design, Setting, and Participants:A randomized clinical trial including infants born at 22 to 28 weeks' gestation and diagnosed with a protocol-defined PDA between the age of 48 hours and 21 days at screening. The trial was conducted from December 2018 to December 2024 at 33 hospitals within the National Institute of Child Health and Human Development Neonatal Research Network. The final date of follow-up was June 2025. Interventions:Infants with PDA were randomized to expectant management (n = 242) or active treatment (n = 240; acetaminophen, ibuprofen, or indomethacin) to close the PDA. Main Outcomes and Measures:The primary outcome was death or BPD at 36 weeks' postmenstrual age. The secondary outcomes included the components of the primary outcome and other morbidities of prematurity. Results:A total of 482 infants were randomized (median gestational age, 25 weeks [IQR, 24 to 27 weeks]; median birth weight, 760 g [IQR, 620 to 935 g]). The trial was stopped for futility and safety after the 50% interim analysis for the primary outcome due to higher survival in the expectant management group. The incidence of death or BPD was 80.9% (195/241) of infants in the expectant management group vs 79.6% (191/240) of infants in the active treatment group (adjusted risk difference, 1.2% [95% CI, -5.7% to 8.1%]; P = .73). The incidence of death before 36 weeks' postmenstrual age was 4.1% (10/241) of infants in the expectant management group vs 9.6% (23/240) of infants in the active treatment group (adjusted risk difference, -5.6% [95% CI, -10.1% to -1.2%]; P = .01). Infections resulting in death occurred in 0.8% (2/241) of infants in the expectant management group vs 3.8% (9/240) of infants in the active treatment group. Conclusions and Relevance:In extremely preterm infants with a protocol-defined PDA, death or BPD did not differ between the expectant management group and the active treatment group. Survival was substantially higher with expectant management. Trial Registration:ClinicalTrials.gov Identifier: NCT03456336.

    2026引用:3
    引用
    AI阅读
    加入学术空间
    2Extraction of Treatments and Responses from Non-Small Cell Lung Cancer Clinical Notes Using Natural Language Processing
    Sonish Sivarajkumar,Subhash Edupuganti, David Lazris, Manisha Bhattacharya, Michael Davis, Devin Dressman, Roby Thomas,Yan Hu, Yang Ren,Hua Xu,Ping Yang,Yufei Huang,

    PURPOSEManual extraction of treatment outcomes from unstructured oncology clinical notes is a significant challenge for real-world evidence (RWE) generation. This study aimed to develop and evaluate a robust natural language processing (NLP) system to automatically extract cancer treatments and their associated RECIST-based response categories (complete response, partial response, stable disease, and progressive disease) from non-small cell lung cancer (NSCLC) clinical notes.METHODSThis retrospective NLP development and validation study used a corpus of 250 NSCLC oncology notes from University of Pittsburgh Medical Center (UPMC) Hillman Cancer Center, annotated by physician experts. An end-to-end NLP pipeline was designed, integrating a rule-based module for entity extraction (treatments and responses) and a machine learning module using biomedical clinical bidirectional encoder representations from transformers for relation classification. The system's performance was evaluated on a held-out test set, with partial external validation for relation extraction on a Mayo Clinic data set.RESULTSThe NLP system achieved high overall accuracy. On the UPMC test set (64 notes), the relation classification model attained an area under the receiver operating characteristic curve of 0.94 and an F1 score of 0.92 for linking treatments with documented responses. The rule-based entity extraction demonstrated a macro-averaged F1 score of 0.87 (precision 0.98, recall 0.81). Although precision was high for chemotherapy and most response types (1.00), recall for cancer surgery was 0.45. External validation at Mayo Clinic showed moderate relation extraction F1 scores (range: 0.51-0.64).CONCLUSIONThe proposed NLP system can reliably extract structured treatment and response information from unstructured NSCLC oncology notes with high accuracy. This automated approach can assist in abstracting critical cancer treatment outcomes from clinical narrative text, thereby streamlining real-world data analysis and supporting the generation of RWE in oncology.

    2026JCO clinical cancer informatics(2026)引用:1
    引用
    AI阅读
    加入学术空间
    3Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting.
    Neel D Pasricha, Stella K Kim, Asim V Farooq, Ethan S Lindgren, Rongshan Yan,Gerami D Seitzman,Matilda F Chan,Jessica G Shantha,Dimitra Skondra,Bennie H Jeng, Winston D Chamberlain, Kathryn A Colby,

    Importance:The current ocular Common Terminology Criteria for Adverse Events (CTCAE) mix eye signs with symptoms and lack standardized clinical photographs and experimental oncology drug dose modification recommendations. Robust reporting of ocular adverse events (AEs) is important to maintain patient safety and to guide the development of novel efficacious drugs. Objective:To develop improved ocular AE grading scales to reliably evaluate and grade ocular AEs in patients on experimental oncology drug therapy and to provide clear drug dose modification recommendations. Design, Setting, and Participants:A collaborative multicenter interspecialty working group consisting of oncologists and academic ophthalmologists from 11 academic centers in the US and ophthalmologists from the US Food and Drug Administration was assembled in February 2023 to form a consensus on new experimental oncology drug-related ocular AE grading scales. The grading scales were released in June 2023. Main Outcomes and Measures:Expert consensus on novel experimental oncology drug-related ocular AE grading scales. Results:Six experimental oncology drug-related ocular AE grading scales were developed with agreement from ophthalmologists and oncologists for use in antibody-drug conjugate clinical trials: visual acuity, eye symptoms, cornea, conjunctiva/sclera, anterior chamber, and retina/posterior segment. Conclusions and Relevance:The new experimental oncology drug-related ocular AE grading scales developed by the consensus panel were developed to be more concise, containing photographs where applicable, and to provide clear drug dose modification recommendations compared with the previous CTCAE. Use of these ocular AE grading scales may allow for more objective and consistent incidence measurements of ocular AEs throughout clinical trials and postmarketing, potentially facilitating safe testing of novel agents that may cause eye toxicity.

    2026JAMA ophthalmology(2026)引用:1
    引用
    AI阅读
    加入学术空间
    4Boolean Network-Based Identification of Optimal Drug Combinations for Prostate Cancer
    Pranabesh Bhattacharjee, Addanki Pratap Kumar,Aniruddha Datta

    Prostate cancer is one of the most common cancers among men in the United States and is a leading cause of cancer-related deaths and the second most common cancer in men worldwide. In this study, we used a Boolean network model to analyze prostate cancer signaling pathways and to identify optimal drug combinations for precision therapy. By integrating publicly available biological signaling pathway data with recent research findings, we developed a comprehensive model that represents protein-protein interactions, gene mutations, and pathway dysregulation. Faults induced by mutations were modeled using the “stuck at 0” or “stuck at 1” fault paradigms, capturing the impact of genetic alterations on pathway behavior. The model was simulated across various drug combinations to determine which therapies could most effectively alleviate the aberrant signaling caused by specific mutations. To quantify therapeutic efficacy, we calculated a Size Difference (SD) score, a metric analogous to Hamming distance, measuring the deviation from normal, for each drug combination and fault scenario. The results revealed that drug combinations involving Berberine, Docetaxel, Olaparib, and Enzalutamide showed promising prediction efficacy (more than 90%), indicating higher therapeutic potential. A distinguishing feature of this work is that, in addition to the standard prostate cancer drugs, we have included Berberine, a non-toxic natural compound with beneficial effects. These computational findings provide a framework for future experimental and clinical validation, which is necessary to confirm the therapeutic relevance of the predicted drug combinations.

    2026Computational biology and chemistry(2026)
    引用
    AI阅读
    加入学术空间
    5Outcomes of Bypass Surgery in Asymptomatic Moyamoya Angiopathy: A Multicenter Study with Propensity-Score Weighting.
    Basel Musmar, Hammam Abdalrazeq, Joanna M Roy,Nimer Adeeb,Elias Atallah,Kareem El Naamani,Ching-Jen Chen, Roland Jabre,Hassan Saad,Jonathan A Grossberg,Adam A Dmytriw,Aman B Patel,

    INTRODUCTION:Asymptomatic moyamoya angiopathy (MMA) is increasingly detected through noninvasive imaging; however, its optimal management remains controversial. This multicenter retrospective cohort study compared outcomes in asymptomatic versus symptomatic MMA patients undergoing surgical revascularization. PATIENTS AND METHODS:A total of 475 patients treated with bypass surgery across multiple academic centers were included, with 56 (11.8%) classified as asymptomatic and 419 (88.2%) as symptomatic. Baseline demographics, surgical characteristics, and outcomes-including perioperative stroke, intraoperative complications, and follow-up stroke events-were collected. Asymptomatic MMA was defined as the absence of any prior ischemic or hemorrhagic stroke, seizures, or other neurological symptoms at the time of diagnosis. Both unadjusted analyses and propensity score weighting using inverse probability of treatment weighting (IPTW) were performed to adjust for potential confounders. RESULTS:In the unadjusted analysis, asymptomatic patients had significantly lower rates of all perioperative strokes (1.7% vs 11.4%; p = 0.05) and intraoperative complications (1.7% vs 11.2%; p = 0.05) compared to symptomatic patients. Additionally, follow-up stroke rates were lower in the asymptomatic group (1.7% vs 11.2%; p = 0.05). After IPTW adjustment, the reduction in intraoperative complications (OR: 0.08, 95% CI: 0.01-0.64; p = 0.01) and follow-up stroke rates (OR: 0.12, 95% CI: 0.01-0.91; p = 0.04) persisted, while differences in overall perioperative stroke were not statistically significant. CONCLUSION:Bypass surgery in selected asymptomatic MMA patients is associated with reduced intraoperative complications, and fewer follow-up stroke rates. These findings support the careful consideration of surgical intervention in asymptomatic patients, emphasizing the importance of patient selection for optimal outcomes.

    2026European stroke journal(2026)
    引用
    AI阅读
    加入学术空间
    立即登录,查看全部 6500 篇论文

    合作机构(100)

    德克萨斯大学奥斯汀分校合作论文 983
    德克萨斯大学卫生科学中心圣安东尼奥分校合作论文 271
    贝勒医学院合作论文 176
    德克萨斯大学休斯顿健康科学中心合作论文 131
    华盛顿大学合作论文 103
    加州大学合作论文 86
    德克萨斯大学西南医学中心合作论文 79
    德克萨斯大学系统合作论文 73
    密歇根大学合作论文 70
    美国国家卫生研究院合作论文 66

    机构统计